Andean Precious Metals (CVE:APM) Upgraded by Desjardins to “Moderate Buy” Rating

Andean Precious Metals (CVE:APM) was upgraded by investment analysts at Desjardins to a “moderate buy” rating in a research note issued to investors on Thursday, Zacks.com reports.

Andean Precious Metals Stock Performance

Shares of Andean Precious Metals stock opened at C$1.65 on Thursday. Andean Precious Metals has a one year low of C$0.55 and a one year high of C$2.18. The stock has a market capitalization of C$246.44 million, a P/E ratio of 4.34 and a beta of 1.22. The stock’s 50 day moving average is C$1.43.

Andean Precious Metals (CVE:APM) last announced its quarterly earnings data on Tuesday, August 13th. The company reported C$0.08 EPS for the quarter, hitting analysts’ consensus estimates of C$0.08. Andean Precious Metals had a return on equity of 41.08% and a net margin of 23.75%. The firm had revenue of C$95.47 million for the quarter. Equities analysts predict that Andean Precious Metals will post 0.3806452 EPS for the current fiscal year.

Insider Buying and Selling at Andean Precious Metals

In other Andean Precious Metals news, insider 2176423 Ontario Ltd. bought 84,400 shares of Andean Precious Metals stock in a transaction on Tuesday, October 8th. The shares were bought at an average price of C$1.51 per share, for a total transaction of C$127,359.60. Insiders have acquired 1,202,800 shares of company stock worth $1,607,032 over the last quarter. 69.37% of the stock is currently owned by company insiders.

Andean Precious Metals Company Profile

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases.